FTC monitoring how Big Pharma reacts to upcoming patent cliffs, official says
Source: SeekingAlpha
2026-03-18 07:39:09 ET
More on Pfizer, Merck, etc.
- Expect Pfizer To Comeback: Take The Dividend While Waiting For Capital Appreciation
- Eli Lilly Reaching For Peak GLP-1 Euphoria: Rotten Trading Momentum Since November
- Eli Lilly: The Weight-Loss Craze Isn't Over
- Lilly cut to Sell equivalent rating at HSBC on valuation concerns
- Pfizer succeeds in mid-stage trial for breast cancer therapy
Read the full article on Seeking Alpha
For further details see:
FTC monitoring how Big Pharma reacts to upcoming patent cliffs, official says
GlaxoSmithKline PLC
NASDAQ: GSK
GSK Trading
0.0% G/L:
$51.91 Last:
2,530,024 Volume:
$52.19 Open:
GSK Latest News
March 13, 2026 11:44:00 am
GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18-49 Years at Increased Risk
February 23, 2026 01:13:00 pm
Bora Pharmaceuticals and GSK Sign $250M Five Year Global Manufacturing Contract
GSK Stock Data
$120,291,791,432
2,019,018,428
0.4%
538
N/A
Pharmaceuticals
Healthcare
GB
London
